What is GMAB's relative strength rating?

GMAB ranks at the 78th percentile over 1 month, 83th percentile over 3 months, 65th percentile over 6 months, 72th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is GMAB in?

GMAB is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is GMAB in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). GMAB benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is GMAB?

GMAB currently shows a 20-day average daily range (ADR%) of 2.2%, a 90-day beta versus the S&P 500 of 0.32. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does GMAB have a seasonal pattern?

TickerStance computes GMAB's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what GMAB has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did GMAB last report earnings?

No SEC EDGAR filings are linked to GMAB in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Genmab A/S ADS (GMAB) · RS 65 · Neutral

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, Genmab A/S ADS (GMAB) has a 3-month relative strength percentile of 83 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 55. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.2%, relative volume 1.17×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month83pctile

6 month65pctile

1 year72pctile

Classic70IBD pctile

LDR90leadership

0 of 5 lenses lit · avg RS pctile 76

!ADR%2.2%✓A/DB!RVOL1.17×✓$ Vol$68M

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

§ Seasonality

10y · since 2022

Best monthNov on averageavg +10.39% · 75% win · n 4

Worst monthJan on averageavg -5.18% · 25% win · n 4

GMAB monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	GMAB Jan avg: -5.18% median: -6.69% win: 25% σ: 8.08% n: 4 2022-04-12 → 2026-07-31	GMAB Feb avg: 0.51% median: -1.74% win: 50% σ: 10.73% n: 4 2022-04-12 → 2026-07-31	GMAB Mar avg: -3.57% median: -4.17% win: 50% σ: 9.56% n: 4 2022-04-12 → 2026-07-31	GMAB Apr avg: 1.27% median: -1.16% win: 40% σ: 6.88% n: 5 2022-04-12 → 2026-07-31	GMAB May avg: -3.65% median: -0.95% win: 20% σ: 6.21% n: 5 2022-04-12 → 2026-07-31	GMAB Jun avg: -0.72% median: -1.38% win: 40% σ: 7.08% n: 5 2022-04-12 → 2026-07-31	GMAB Jul avg: 8.20% median: 8.81% win: 100% σ: 3.25% n: 5 2022-04-12 → 2026-07-31	GMAB Aug avg: 1.31% median: -1.05% win: 25% σ: 9.48% n: 4 2022-04-12 → 2026-07-31 (current)	GMAB Sep avg: -1.58% median: -8.68% win: 25% σ: 16.70% n: 4 2022-04-12 → 2026-07-31	GMAB Oct avg: -3.70% median: -7.58% win: 25% σ: 16.69% n: 4 2022-04-12 → 2026-07-31	GMAB Nov avg: 10.39% median: 12.21% win: 75% σ: 10.25% n: 4 2022-04-12 → 2026-07-31	GMAB Dec avg: -3.99% median: -3.88% win: 25% σ: 4.01% n: 4 2022-04-12 → 2026-07-31

Evidence · 1 of 3

Receipts behind the read

3 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

78

3m

83

6m

65

1y

72

LDR

—

StageWeinstein stage analysis

Stage 1 · Basing

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · GMAB

Does the business back the chart?

No SEC filings on file for this ticker. Fundamentals section requires EDGAR coverage.

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
GMAB
83RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

CYTKCytokinetics Inc.65 IGCIGC Pharma, Inc.65 ACIUAC Immune SA65 NKTXNkarta, Inc. Common Stock64

ETF OWNERS

ETFs holding GMAB

GMAB is held by 8 ETFs as of May 2026. Top owner: AVDE at 0.08% weight, $13M notional. Top 3 carry $19M.

Held by 20 ETFs · $185M across latest filings · largest weight 2.78% (FBT).

ETFs holding: 8
Total value: $20M
Top 3 concentration: 92.4%
Max weight: CANC · 2.37%

Top 8 by value, from SEC N-PORT-P filings dated May 2026.

ETFs holding GMAB ranked by value
ETF	Weight	Value	Δ
AVDE	0.08%	$13M	—
CANC	2.37%	$4M	−0.75 pp
APIE	0.09%	$926K	−0.03 pp
ONEQ	0.01%	$684K	—
AVIV	0.03%	$460K	−0.02 pp
AVSD	0.05%	$228K

Public attention · GMAB

Is the crowd watching?

28/ 100 · vs its own 90-day norm▼ 29 vs 7dStealth leader

Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Floatn/a

Shares out614.6Mshares

Market cap$20.3BLarge Cap

FAQ

Frequently asked questions

What is GMAB's relative strength rating?: GMAB ranks at the 78th percentile over 1 month, 83th percentile over 3 months, 65th percentile over 6 months, 72th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is GMAB in?: GMAB is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is GMAB in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). GMAB benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is GMAB?: GMAB currently shows a 20-day average daily range (ADR%) of 2.2%, a 90-day beta versus the S&P 500 of 0.32. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does GMAB have a seasonal pattern?: TickerStance computes GMAB's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what GMAB has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

APPEARS IN

Featured in these lists

2 lists

Human Therapeutics theme ADR Tight

Genmab A/S ADS (GMAB) — Stance & relative strength

Lenses lit

Market backdrop

§ Seasonality

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding GMAB

Is the crowd watching?

Company snapshot

Frequently asked questions

Featured in these lists

How much does it move?

§ Seasonality

Genmab A/S ADS (GMAB) — Stance & relative strength

GMAB is on the watchlist, not confirmed. 3m RS is 83, Market Stance is mixed at 47.8, A/D rating B

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding GMAB

Is the crowd watching?

Company snapshot

Frequently asked questions

Featured in these lists

How much does it move?